Niacin and Risk of Cardiovascular Events: Deciphering the Paradox.

This article focuses on recent research elucidating the "niacin paradox" in cardiovascular disease (CVD), where niacin lowers LDL cholesterol but does not reduce major adverse cardiovascular events (MACE). The study by Ferrell et al. identifies two terminal metabolites of excess niacin—N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY)—as novel risk factors associated with increased residual CVD risk and vascular inflammation. These findings suggest that elevated levels of 2PY and 4PY promote vascular adhesion molecule 1 (VCAM-1) expression, contributing to CVD beyond traditional lipid-related mechanisms. The study raises important considerations for clinical practice, including the reevaluation of niacin food fortification and supplement use, and highlights the need for further research into niacin metabolites as targets for reducing residual cardiovascular risk.